课题基金 / 基金详情

ASSAYS OF TUMOR RESPONSE TO RADIOTHERAPY

ASSAYS OF TUMOR RESPONSE TO RADIOTHERAPY
肿瘤对放射治疗的反应分析
批准号:
3184089
负责人:
RALPH R WEICHSELBAUM
金额:
$25.39万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1986
资助国家:
美国
项目状态:
已结题
起止时间:
1986-02-01 至 1995-04-30

项目摘要

项目成果

RALPH R WEICHSELBAUM的其他基金

相关文献

中文摘要
翻译
放射治疗是现代癌症治疗的重要组成部分。
英文摘要
Radiotherapy is an important component of modern cancer treatment. Identification of patients most likely to benefit from treatment with ionizing radiation might improve the therapeutic ratio. We propose to continue to investigate the hypothesis that the presence of radioresistant and/or repair proficient cells in human tumors predicts radiotherapy failure. Therefore, we will establish early-passage cultures of human tumor cell lines from biopsies of head-and-neck carcinomas and soft-tissue sarcomas derived from patients prior to radiotherapy. We will then study the radiosensitivity and repair of radiation damage in these human tumor cells and correlate our in vitro findings with radiocurability measured in terms of local control and total survival. Our studies will include: 1) determination of D0, n, D derived from survival at doses of 100-1100 cGy (3 logs cell kill), survival at 200 cGy; 2) measurement of sublethal damage repair (SLDR) in exponentially-growing cultures of these early-passage tumor cells; determination of the repair of potentially lethal damage (PLDR) employing PLDR survival curves (100-1100 cGy) at 0 and 24 hrs. PLDR time and time course PLDR experiments following a single dose and subculture at various time points from plateau phase cultures; 3) measurement of the induction and rejoining of DNA double-strand breaks in first-passage, exponentially-growing cultures of human head-and-neck and soft-tissue sarcoma cell lines. The radiobiological parameter(s) that is(are) the biological basis of radiotherapy failure or success and predicts clinical outcome may emerge from our investigation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
In vivo CRISPR-screening of novel cancer cell-intrinsic targets that sensitize to local ionizing radiation, and possible combination with systemic checkpoint blockade.
  • 批准号:
    10684850
  • 项目类别:
  • 资助金额:
    $18.48万
  • 财政年份:
    2022
  • 负责人:
    RALPH R WEICHSELBAUM
  • 依托单位:
In vivo CRISPR-screening of novel cancer cell-intrinsic targets that sensitize to local ionizing radiation, and possible combination with systemic checkpoint blockade.
  • 批准号:
    10512896
  • 项目类别:
  • 资助金额:
    $24.08万
  • 财政年份:
    2022
  • 负责人:
    RALPH R WEICHSELBAUM
  • 依托单位:
Elucidating the Roles of RNA m6A readers Y1 and Y2 in radiation-induced immunity and immunotherapy
  • 批准号:
    10418794
  • 项目类别:
  • 资助金额:
    $40.45万
  • 财政年份:
    2021
  • 负责人:
    RALPH R WEICHSELBAUM
  • 依托单位:
Elucidating the Roles of RNA m6A readers Y1 and Y2 in radiation-induced immunity and immunotherapy
  • 批准号:
    10279950
  • 项目类别:
  • 资助金额:
    $41.27万
  • 财政年份:
    2021
  • 负责人:
    RALPH R WEICHSELBAUM
  • 依托单位: